AMGN Amgen

Q2 2025 10-Q

Filed: Aug 6, 2025Period ending Jun 30, 2025

Health Care

Biological Products, (No Diagnostic Substances)SEC EDGAR

Amgen (AMGN) 10-Q quarterly report for Q2 2025, filed with SEC EDGAR on Aug 6, 2025 for the fiscal period ending Jun 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q2 2025 10-Q

Risk Factors

• Financial risk: investment portfolio exposure to market fluctuations, impairments possible from interest rate hikes, inflation, and geopolitical events
• Financial risk: cash deposits exceed insured limits at multinational banks, risking delayed or inaccessible uninsured funds if institutions fail

+1 more insights

Quarterly Financial Summary
XBRL

Revenue

$9.2B

▲ +9.4% YoY▲ +12.6% QoQ

Net Income

$1.4B

▲ +92.0% YoY▼ -17.2% QoQ

Operating Margin

28.9%

▲ +618bp YoY▲ +1448bp QoQ

Net Margin

15.6%

▲ +671bp YoY▼ -563bp QoQ

EPS (Diluted)

$2.64

▲ +91.3% YoY▼ -17.5% QoQ

Operating Cash Flow

$2.3B

▼ -7.3% YoY▲ +63.9% QoQ

Source: XBRL data from Amgen Q2 2025 10-Q filing on SEC EDGAR. All figures in USD.

Other Amgen Quarterly Reports

Q3 2025 10-Q

Q1 2025 10-Q

Get deeper insights on Amgen

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.